Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

Abstract

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched Pubmed and EMBASE up to August 20, 2020, to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of ICU admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RR), and 95% confidence intervals (CI) were calculated using a random-effects model. 34 adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14/34 adult studies included only hospitalized patients). The risk of death amongst adult patients was 34% (95% CI 28-39, N=3240) in this sample of predominantly hospitalized patients. Patients aged >60 years had a significantly higher risk of death than patients <60 years (RR 1.82, 95% CI 1.45-2.27, N=1169). The risk of death in pediatric patients was 4% (95% CI 1-9, N=102). The RR of death comparing patients with recent systemic anti-cancer therapy to no treatment was 1.17 (95% CI 0.83-1.64; N=736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients >60 years have significantly higher mortality, and pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.

Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

“…Attenuation of immune responsiveness may, indeed, be advantageous in COVID-19. Some COVID-19 clinical studies indicate poorer outcomes for cancer patients, especially those with hematological cancers ( Pinato et al., 2020 ; Shah et al., 2020 ; Vijenthira et al., 2020 ; Williamson et al., 2020 ), but not others ( Lee et al., 2020 ; Russell et al., 2020b ). Insight into the impact of SARS-CoV-2 on cancer patients' immune status is lacking.…”

Under COVID of the night

“…In this issue of Blood , Vijenthira and colleagues report that patients who have 2 life-threatening conditions, a hematologic malignancy and infection with the virulent microbe COVID-19, face a risk of dying that is ∼1 in 3. 1 …”

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma

“…In both a pooled analysis of 23 studies encompassing data from 412 patients with MM and a retrospective study conducted by the International Myeloma Working Group that included 650 patients with MM and COVID-19, the estimated risk of death due to COVID-19 was 33%. 5 , 6 Male gender, older age, active disease status, and renal impairment have been identified as independent prognostic factors for mortality among hospitalized MM patients with COVID-19. 6 Taking into consideration all the above, there is an urgent need to protect patients with MM from SARS-CoV-2 infection.…”